Related Experiment Video

Updated: Feb 25, 2026

Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
09:38

Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease

Published on: November 14, 2017

15.8K

Polymorphisms of MTHFR, eNOS, ACE, AGT, ApoE, PON1, PDE4D, and Ischemic Stroke: Meta-Analysis

Loo Keat Wei1, Anthony Au2, Saras Menon3

  • 1Department of Biological Science, Faculty of Science, Universiti Tunku Abdul Rahman, Bandar Barat, Kampar, Perak, Malaysia.

Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association
|August 2, 2017
PubMed
Abstract

Insights

Genetic polymorphisms in MTHFR, eNOS, PDE4D, ACE, AGT, PON1, and ApoE are linked to increased ischemic stroke risk. This meta-analysis clarifies the genetic predisposition to ischemic stroke for these key genes.

Area of Science:

  • Genetics
  • Cardiovascular Disease Epidemiology
  • Molecular Biology

Background:

  • The relationship between specific genetic variations and ischemic stroke risk is not fully understood.
  • Genetic polymorphisms in key genes like MTHFR, eNOS, PDE4D, ACE, AGT, PON1, and ApoE have been investigated for their potential role in ischemic stroke.
  • Previous studies have yielded inconclusive results, necessitating a comprehensive meta-analysis.

Purpose of the Study:

  • To conduct an updated meta-analysis to clarify the association between various genetic polymorphisms and ischemic stroke.
  • To pool data from numerous case-control studies to determine the influence of genetic factors on ischemic stroke risk.
  • To provide a clearer understanding of genetic predispositions to ischemic stroke.

Main Methods:

  • Systematic identification of case-control studies across multiple languages.
  • Calculation of pooled odds ratios (ORs) and 95% confidence intervals (CIs) using fixed- and random-effect models.
  • Performance of sensitivity analysis, heterogeneity testing, Hardy Weinberg Equilibrium checks, and Egger's regression analysis.

Main Results:

  • Analysis of 490 studies involving 138,592 cases and 159,314 controls.
  • Significant associations found between MTHFR (677TT, 1298CC), eNOS (+894TT, VNTR), PDE4D (SNP 83), ACE (DD), AGT (235TT), PON1 (192RR), and ApoE (ε4) polymorphisms and increased ischemic stroke risk.
  • No association was found between PDE4D (SNP 87) and eNOS (-786T>C) polymorphisms and ischemic stroke risk.

Conclusions:

  • Genetic polymorphisms in MTHFR, eNOS, PDE4D (SNP 83), ACE, AGT, PON1, and ApoE are confirmed to predispose individuals to ischemic stroke.
  • The findings provide robust evidence for the role of these specific genetic variations in ischemic stroke pathogenesis.
  • This meta-analysis offers valuable insights for understanding genetic risk factors in ischemic stroke.
Keywords:
ACEAGTApoEIschemic strokeMTHFRPDE4DPON1eNOS

More Related Videos

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease09:34

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

34.9K
High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

12.3K

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
57
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
51
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
49
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
36
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
67
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
75